Insider Selling: Aquestive Therapeutics (NASDAQ:AQST) SVP Sells $105,546.87 in Stock

Aquestive Therapeutics, Inc. (NASDAQ:AQST) SVP Melina Cioffi sold 25,311 shares of the company’s stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $4.17, for a total value of $105,546.87. Following the sale, the senior vice president owned 274,867 shares of the company’s stock, valued at $1,146,195.39. This trade represents a 8.43% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Aquestive Therapeutics Price Performance

Shares of AQST stock opened at $4.02 on Friday. The stock’s 50-day moving average is $3.99 and its 200 day moving average is $5.20. Aquestive Therapeutics, Inc. has a 1-year low of $2.12 and a 1-year high of $7.55. The company has a market cap of $490.60 million, a P/E ratio of -5.15 and a beta of 1.61.

Aquestive Therapeutics (NASDAQ:AQST) last announced its earnings results on Wednesday, March 4th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.13). The business had revenue of $13.02 million for the quarter, compared to analyst estimates of $13.28 million. On average, analysts anticipate that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current year.

Key Stories Impacting Aquestive Therapeutics

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: HC Wainwright issued a more favorable near‑term earnings outlook and raised some FY estimates, offering modest analytical support if operational/regulatory progress continues. HC Wainwright Estimates
• Neutral Sentiment: Coverage pieces (market commentary) explain recent volatility and provide context for regulatory risk tied to Anaphylm; these explain price moves but do not change fundamentals immediately. AAII: Why AQST Is Down
• Neutral Sentiment: Short‑interest figures circulating this week show anomalous zero/NaN values (likely reporting error) and should not be used to support a short‑squeeze thesis until official confirmations are posted. (No authoritative link provided.)
• Negative Sentiment: Multiple law firms have filed or advertised class actions for purchasers between June 16, 2025 and Jan 8, 2026; several solicitations for lead‑plaintiff roles raise the prospect of material litigation costs, management distraction, and downside risk to the stock. Rosen Law Firm Notice
• Negative Sentiment: Additional class‑action notices from other firms (Pomerantz, Faruqi, Bernstein, Portnoy) amplify the legal narrative and extend the timeline of investor uncertainty. Pomerantz Alert
• Negative Sentiment: Insider selling: a disclosed sale (15,741 shares by Sherry Korczynski and other senior officer transactions) at roughly $4.17 reduces insider holdings and is often interpreted negatively by the market. InsiderTrades: Insider Sale
• Negative Sentiment: A PR Newswire item highlights an allegation tied to an analyst’s large price‑target cut (Cantor), linking that cut to a sharp one‑day selloff; this adds to reputational/regulatory narrative around prior communications and approval risk for Anaphylm. PR Newswire: Analyst Lawsuit

Hedge Funds Weigh In On Aquestive Therapeutics

Several hedge funds have recently modified their holdings of the stock. Victory Capital Management Inc. increased its holdings in shares of Aquestive Therapeutics by 17.0% during the third quarter. Victory Capital Management Inc. now owns 12,794 shares of the company’s stock valued at $72,000 after acquiring an additional 1,862 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Aquestive Therapeutics by 6.0% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 47,098 shares of the company’s stock worth $156,000 after purchasing an additional 2,649 shares in the last quarter. Informed Momentum Co LLC grew its position in Aquestive Therapeutics by 1.8% during the 4th quarter. Informed Momentum Co LLC now owns 155,053 shares of the company’s stock worth $1,002,000 after purchasing an additional 2,721 shares during the last quarter. Stifel Financial Corp grew its position in Aquestive Therapeutics by 0.9% during the 4th quarter. Stifel Financial Corp now owns 369,728 shares of the company’s stock worth $2,388,000 after purchasing an additional 3,300 shares during the last quarter. Finally, AQR Capital Management LLC increased its stake in Aquestive Therapeutics by 6.8% during the 4th quarter. AQR Capital Management LLC now owns 61,709 shares of the company’s stock valued at $399,000 after purchasing an additional 3,934 shares in the last quarter. Institutional investors and hedge funds own 32.45% of the company’s stock.

Analysts Set New Price Targets

AQST has been the subject of a number of analyst reports. Wall Street Zen raised shares of Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. Lake Street Capital set a $6.00 price target on shares of Aquestive Therapeutics in a report on Tuesday, February 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Wednesday, January 21st. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $8.80.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.